These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 28611859)

  • 21. Ipragliflozin effectively reduced visceral fat in Japanese patients with type 2 diabetes under adequate diet therapy.
    Yamamoto C; Miyoshi H; Ono K; Sugawara H; Kameda R; Ichiyama M; Yamamoto K; Nomoto H; Nakamura A; Atsumi T
    Endocr J; 2016 Jun; 63(6):589-96. PubMed ID: 27052123
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ipragliflozin Reduces Epicardial Fat Accumulation in Non-Obese Type 2 Diabetic Patients with Visceral Obesity: A Pilot Study.
    Fukuda T; Bouchi R; Terashima M; Sasahara Y; Asakawa M; Takeuchi T; Nakano Y; Murakami M; Minami I; Izumiyama H; Hashimoto K; Yoshimoto T; Ogawa Y
    Diabetes Ther; 2017 Aug; 8(4):851-861. PubMed ID: 28616806
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of Visceral Fat Reduction by Ipragliflozin and Metformin in Elderly Type 2 Diabetes Patients: Sub-Analysis of a Randomized-Controlled Study.
    Koshizaka M; Ishikawa K; Ishibashi R; Takahashi S; Sakamoto K; Yokoh H; Baba Y; Ide S; Ide K; Ishikawa T; Onishi S; Kobayashi K; Takemoto M; Horikoshi T; Shimofusa R; Maezawa Y; Yokote K
    Diabetes Ther; 2021 Jan; 12(1):183-196. PubMed ID: 33098565
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of Ipragliflozin on Diabetic Nephropathy and Blood Pressure in Patients With Type 2 Diabetes: An Open-Label Study.
    Ito D; Ikuma-Suwa E; Inoue K; Kaneko K; Yanagisawa M; Inukai K; Noda M; Shimada A
    J Clin Med Res; 2017 Feb; 9(2):154-162. PubMed ID: 28090231
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antihyperglycemic effect of ipragliflozin, a sodium-glucose co-transporter 2 inhibitor, in combination with oral antidiabetic drugs in mice.
    Takasu T; Hayashizaki Y; Tahara A; Kurosaki E; Takakura S
    Clin Exp Pharmacol Physiol; 2015 Jan; 42(1):87-93. PubMed ID: 25311502
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comprehensive efficacy of ipragliflozin on various conditioned type 2 diabetes compared with dipeptidyl peptidase-4 inhibitors and with both agents, based on a real-world multicenter trial.
    Sawano F; Kamei N; Miyahara M; Kobuke K; Nakanishi S; Nagano C; Nojima H; Maeda S; Watanabe H; Kishimoto R; Yamashita M; Hamaoka A; Mukai K; Tsuboi T; Mochizuki H; Nakashima R; Sakashita Y; Morishita H; Kitamura T
    Diabetol Int; 2021 Oct; 12(4):364-378. PubMed ID: 34567919
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of metabolic parameters and body composition in Japanese patients with type 2 diabetes mellitus who were administered tofogliflozin for 48 weeks.
    Iwahashi Y; Hirose S; Nakajima S; Seo A; Takahashi T; Tamori Y
    Diabetol Int; 2017 Jun; 8(2):205-211. PubMed ID: 30603323
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of the SGLT2 inhibitor ipragliflozin on food intake, appetite-regulating hormones, and arteriovenous differences in postprandial glucose levels in type 2 diabetic rats.
    Tahara A; Kondo Y; Takasu T; Tomiyama H
    Biomed Pharmacother; 2018 Sep; 105():1033-1041. PubMed ID: 30021338
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of Sodium Glucose Co-Transporter 2 Inhibitors in Type 1 Diabetes Mellitus on Body Composition and Glucose Variabilities: Single-Arm, Exploratory Trial.
    Baba Y; Ishibashi R; Takasaki A; Ito C; Watanabe A; Tokita M; Meguro M; Harama T; Hirayama K; Yamamoto T; Nakamura S; Koshizaka M; Maezawa Y; Uchida D; Okajima F
    Diabetes Ther; 2021 May; 12(5):1415-1427. PubMed ID: 33738773
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Twenty-four-week effects of liraglutide on body composition, adherence to appetite, and lipid profile in overweight and obese patients with type 2 diabetes mellitus.
    Rondanelli M; Perna S; Astrone P; Grugnetti A; Solerte SB; Guido D
    Patient Prefer Adherence; 2016; 10():407-13. PubMed ID: 27069358
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase 3 randomized placebo-controlled trial to assess the efficacy and safety of ipragliflozin as an add-on therapy to metformin in Russian patients with inadequately controlled type 2 diabetes mellitus.
    Shestakova MV; Wilding JPH; Wilpshaar W; Tretter R; Orlova VL; Verbovoy AF
    Diabetes Res Clin Pract; 2018 Dec; 146():240-250. PubMed ID: 30391333
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial.
    Han E; Lee YH; Lee BW; Kang ES; Cha BS
    J Clin Med; 2020 Jan; 9(1):. PubMed ID: 31963648
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Open-Label Study to Assess the Efficacy of Ipragliflozin for Reducing Insulin Dose in Patients with Type 2 Diabetes Mellitus Receiving Insulin Therapy.
    Ishihara H; Yamaguchi S; Sugitani T; Kosakai Y
    Clin Drug Investig; 2019 Dec; 39(12):1213-1221. PubMed ID: 31552641
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term effects of ipragliflozin and pioglitazone on metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes: 5 year observational follow-up of a randomized, 24 week, active-controlled trial: Effect of ipragliflozin in MASLD.
    Ito D; Shimizu S; Haisa A; Yanagisawa S; Inoue K; Saito D; Sumita T; Yanagisawa M; Uchida Y; Inukai K; Shimada A
    J Diabetes Investig; 2024 May; ():. PubMed ID: 38775319
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glycemic Control with Ipragliflozin, a Novel Selective SGLT2 Inhibitor, Ameliorated Endothelial Dysfunction in Streptozotocin-Induced Diabetic Mouse.
    Salim HM; Fukuda D; Yagi S; Soeki T; Shimabukuro M; Sata M
    Front Cardiovasc Med; 2016; 3():43. PubMed ID: 27833913
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination treatment with ipragliflozin and metformin: a randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus.
    Veltkamp SA; van Dijk J; Collins C; van Bruijnsvoort M; Kadokura T; Smulders RA
    Clin Ther; 2012 Aug; 34(8):1761-71. PubMed ID: 22795925
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of ipragliflozin, a selective sodium-glucose co-transporter 2 inhibitor, on blood pressure in Japanese patients with type 2 diabetes mellitus: a pooled analysis of six randomized, placebo-controlled clinical trials.
    Kashiwagi A; Yoshida S; Kawamuki K; Nakamura I; Kazuta K; Ueyama E; Takahashi H; Akiyama N; Kondo Y; Ogihara T
    Diabetol Int; 2017 Mar; 8(1):76-86. PubMed ID: 30603310
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of the SGLT2 inhibitor ipragliflozin on various diabetic symptoms and progression of overt nephropathy in type 2 diabetic mice.
    Tahara A; Takasu T
    Naunyn Schmiedebergs Arch Pharmacol; 2018 Apr; 391(4):395-406. PubMed ID: 29374293
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice.
    Tahara A; Kurosaki E; Yokono M; Yamajuku D; Kihara R; Hayashizaki Y; Takasu T; Imamura M; Li Q; Tomiyama H; Kobayashi Y; Noda A; Sasamata M; Shibasaki M
    Eur J Pharmacol; 2013 Sep; 715(1-3):246-55. PubMed ID: 23707905
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of the combination of SGLT2 selective inhibitor ipragliflozin and various antidiabetic drugs in type 2 diabetic mice.
    Tahara A; Takasu T; Yokono M; Imamura M; Kurosaki E
    Arch Pharm Res; 2016 Feb; 39(2):259-270. PubMed ID: 26450351
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.